Immunity and vaccine development efforts against Trypanosoma cruzi

Lizette E. Rios, Juan Carlos Vázquez-Chagoyán, Antonio Ortega Pacheco, M. Paola Zago, Nisha J. Garg

Research output: Contribution to journalReview article

Abstract

Trypanosoma cruzi (T. cruzi) is the causative agent for Chagas disease (CD). There is a critical lack of methods for prevention of infection or treatment of acute infection and chronic disease. Studies in experimental models have suggested that the protective immunity against T. cruzi infection requires the elicitation of Th1 cytokines, lytic antibodies and the concerted activities of macrophages, T helper cells, and cytotoxic T lymphocytes (CTLs). In this review, we summarize the research efforts in vaccine development to date and the challenges faced in achieving an efficient prophylactic or therapeutic vaccine against human CD.

Original languageEnglish (US)
Article number105168
JournalActa Tropica
Volume200
DOIs
StatePublished - Dec 2019

Fingerprint

Trypanosoma cruzi
vaccine development
Immunity
Chagas disease
Vaccines
Chagas Disease
immunity
Infection
infection
cytotoxic T-lymphocytes
Cytotoxic T-Lymphocytes
Acute Disease
Helper-Inducer T-Lymphocytes
chronic diseases
macrophages
Chronic Disease
cytokines
Theoretical Models
T-lymphocytes
Macrophages

Keywords

  • Adjuvants
  • Chagas
  • Immunity
  • Prophylactic
  • Therapeutic
  • Vaccine

ASJC Scopus subject areas

  • Parasitology
  • veterinary (miscalleneous)
  • Insect Science
  • Infectious Diseases

Cite this

Rios, L. E., Vázquez-Chagoyán, J. C., Pacheco, A. O., Zago, M. P., & Garg, N. J. (2019). Immunity and vaccine development efforts against Trypanosoma cruzi. Acta Tropica, 200, [105168]. https://doi.org/10.1016/j.actatropica.2019.105168

Immunity and vaccine development efforts against Trypanosoma cruzi. / Rios, Lizette E.; Vázquez-Chagoyán, Juan Carlos; Pacheco, Antonio Ortega; Zago, M. Paola; Garg, Nisha J.

In: Acta Tropica, Vol. 200, 105168, 12.2019.

Research output: Contribution to journalReview article

Rios, Lizette E. ; Vázquez-Chagoyán, Juan Carlos ; Pacheco, Antonio Ortega ; Zago, M. Paola ; Garg, Nisha J. / Immunity and vaccine development efforts against Trypanosoma cruzi. In: Acta Tropica. 2019 ; Vol. 200.
@article{99aae42e7ded4612a03145c966f14c12,
title = "Immunity and vaccine development efforts against Trypanosoma cruzi",
abstract = "Trypanosoma cruzi (T. cruzi) is the causative agent for Chagas disease (CD). There is a critical lack of methods for prevention of infection or treatment of acute infection and chronic disease. Studies in experimental models have suggested that the protective immunity against T. cruzi infection requires the elicitation of Th1 cytokines, lytic antibodies and the concerted activities of macrophages, T helper cells, and cytotoxic T lymphocytes (CTLs). In this review, we summarize the research efforts in vaccine development to date and the challenges faced in achieving an efficient prophylactic or therapeutic vaccine against human CD.",
keywords = "Adjuvants, Chagas, Immunity, Prophylactic, Therapeutic, Vaccine",
author = "Rios, {Lizette E.} and V{\'a}zquez-Chagoy{\'a}n, {Juan Carlos} and Pacheco, {Antonio Ortega} and Zago, {M. Paola} and Garg, {Nisha J.}",
year = "2019",
month = "12",
doi = "10.1016/j.actatropica.2019.105168",
language = "English (US)",
volume = "200",
journal = "Acta Tropica",
issn = "0001-706X",
publisher = "Elsevier",

}

TY - JOUR

T1 - Immunity and vaccine development efforts against Trypanosoma cruzi

AU - Rios, Lizette E.

AU - Vázquez-Chagoyán, Juan Carlos

AU - Pacheco, Antonio Ortega

AU - Zago, M. Paola

AU - Garg, Nisha J.

PY - 2019/12

Y1 - 2019/12

N2 - Trypanosoma cruzi (T. cruzi) is the causative agent for Chagas disease (CD). There is a critical lack of methods for prevention of infection or treatment of acute infection and chronic disease. Studies in experimental models have suggested that the protective immunity against T. cruzi infection requires the elicitation of Th1 cytokines, lytic antibodies and the concerted activities of macrophages, T helper cells, and cytotoxic T lymphocytes (CTLs). In this review, we summarize the research efforts in vaccine development to date and the challenges faced in achieving an efficient prophylactic or therapeutic vaccine against human CD.

AB - Trypanosoma cruzi (T. cruzi) is the causative agent for Chagas disease (CD). There is a critical lack of methods for prevention of infection or treatment of acute infection and chronic disease. Studies in experimental models have suggested that the protective immunity against T. cruzi infection requires the elicitation of Th1 cytokines, lytic antibodies and the concerted activities of macrophages, T helper cells, and cytotoxic T lymphocytes (CTLs). In this review, we summarize the research efforts in vaccine development to date and the challenges faced in achieving an efficient prophylactic or therapeutic vaccine against human CD.

KW - Adjuvants

KW - Chagas

KW - Immunity

KW - Prophylactic

KW - Therapeutic

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85072582586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072582586&partnerID=8YFLogxK

U2 - 10.1016/j.actatropica.2019.105168

DO - 10.1016/j.actatropica.2019.105168

M3 - Review article

C2 - 31513763

AN - SCOPUS:85072582586

VL - 200

JO - Acta Tropica

JF - Acta Tropica

SN - 0001-706X

M1 - 105168

ER -